The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

CWA Asset Management Group LLC trimmed its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) ...

Nordea Investment Management AB increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 19.4% during the fourth quarter, Holdings Channel reports. The ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

Published first on TheFly – the ul The FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared to the blockbuster drug Trikafta.

Orphan Medicines, led by the gene therapy Zolgensma and the Cystic Fibrosis treatment Trikafta were the most successful launches according to IQVIA list price sales data in Europe in 2020 (figure 2).

The division, which will expand on the already-existing Released Soldiers’ Division and Fund, will include a dedicated branch for reservists’ welfare and be led by Col. (res.) Eyal Hans ...